Efficacité et innocuité de l'Ixekizumab versus Adalimumab chez des patients naïfs de produits biologiques atteints de rhumatisme psoriasique actif et de psoriasis modéré à sévère: Résultats de l'étude randomisée SPIRIT-H2H à 52 semaines
Dermatol Pract Concept. 2022 doi: 10.5826/dpc.1202a104
Ixekizumab (IXE)-treated patients achieved significantly greater simultaneous PASI100 and ACR50 responses through W52 versus adalimumab (ADA)-treated, confirming IXE as an efficacious and safe treatment. This study investigated the efficacy and safety of IXE and ADA in the subgroup of patients with PsA and moderate-to-severe PsO through W52.
A comparison of the results of this analysis with those of other studies confirms the efficacy of IXE in treating nail PsO in patients with moderate-to-severe PsO, irrespective of concomitant active PsA. These results increase awareness of available treatment options and inform evidence-based clinical decisions for patients with active PsA and moderate-to-severe PsO.
Keywords:
